### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response..

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)															
1. Name and Address of Reporting Person * Saks Samuel R				2. Issuer Name <b>and</b> Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVENUE, SUITE 306				3. Date of Earliest Transaction (Month/Day/Year) 06/12/2018							Year)		Officer (give	title below)		(specify below	v)
NEW YORK, NY 10022				4. If Amendment, Date Original Filed(Month/Day/Year)							Day/Year)	_X_ F	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person				
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui							e Securities A	Acquired,	ired, Disposed of, or Beneficially Owned				
1.Title of S (Instr. 3)	ecurity		2. Transaction Date (Month/Day/Year	2A. Dee Execution (Month/	on D	ate, if	Code (Inst		(A (Ir	() oi	r Disposed of 3, 4 and 5)  (A) or and (D) P	(D) Owne Trans		ecurities Berng Reported	1 ( F I C	orm:	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Persons who respond to the collection of information contained SEC 1474 (9-02) in this form are not required to respond unless the form displays a currently valid OMB control number.  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of	2.	3. Transaction	3A. Deemed	( <i>e.g.</i> , puts		IIs, wari 5. Numb						es) 7. Title an	đ	8 Price of	9. Number o	10.	11. Nature
	Conversion		Execution Date, if	Transaction Code	on of I		ve es d	Expiration Date (Month/Day/Year) L S		Amount o Underlyin Securities	mount of iderlying		Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownersl Form of Derivati Security Direct (I or Indire	of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exerci	sable		Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$ 4.25	06/12/2018		A	2	20,000		06/12	/2019 <mark>(</mark>	(1)	06/12/2028	Common	20,000	\$ 0 <u>(1)</u>	20,000	D	

## **Reporting Owners**

Demostra Commun Name / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Saks Samuel R C/O TONIX PHARMACEUTICALS HOLDING CORP. 509 MADISON AVENUE, SUITE 306 NEW YORK, NY 10022	X					

# **Signatures**

/s/ Jessica Morris, Attorney-in-Fact	06/13/2018
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.